ai
Multi-Analyte Liquid Biopsy
At Oncophenomics, we’re leading the way in personalized cancer care with our state-of-the-art liquid biopsy tests. Our innovative approach allows for early detection, personalized treatment selection, monitoring for minimal residual disease, and overcoming drug resistance.
What we Do
Early Detection
At Oncophenomics, we’re leading the way in personalized medicine, improving patient outcomes through our cutting-edge liquid biopsy tests. Our innovative approach allows for early detection and personalized treatment selection, unlocking the potential of PARP inhibitors, monitoring minimal residual disease (MRD), and overcoming drug resistance.
Enabling Personalized Treatment
Improve Clinical Outcomes
Monitor Response to Treatment
Comprehensive
Genomic Profiling for both tissue and liquid biopsy enables us to custom-tailor the treatments unique to each patient
GPU for Genomics
We have built both cloud and offline servers customized for handling large genomics datasets
Machine Learning
Algorithms to query custom large language inference models (Variant-GPT, Bio-GPT) for clinical interpretation of key genomic findings
Bioinformatics
Custom Bioinformatics Data Analysis Pipelines built with Nextflow form the core of our technology. Fully automated streamlined Raw data to Reports
R&D
Research & Development
Our state-of-the-art liquid biopsy tests enable early detection of cancer, providing unprecedented insights into the disease. By analyzing circulating tumor DNA, we can identify genetic alterations and monitor treatment response, allowing for personalized treatment selection.
Revolutionizing Cancer Diagnostics
Unleashing the Potential of Liquid Biopsy
Detecting Minimal Residual Disease
Clients
We work with Biotech, Biopharma, Cancer Hospitals & Oncologists
Discover the power of comprehensive genomic profiling and its ability to revolutionize targeted therapies. Our state-of-the-art liquid biopsy tests provide invaluable insights for personalized treatment selection.
Paitent Selection for Clinical Trials
Biomarkers as End Points
Clinical & Translational Cancer Research
Have a custom project?
By leveraging our multi-omics multi-analyte liquid biopsy technology we can support multiple use cases from discovery to clinical stage
Browse existing case studies and products
Coming soon…
Company
Suite 104, 1st Floor, Inspire Infra-Horizon, Future Kids School Road, Financial District, Nanakramguda, Hyderabad, Telangana-500032